Rapid Review Quiz: Nonalcoholic Fatty Liver Disease (NAFLD)

B.S. Anand, MD


May 27, 2022

According to a recent systematic review, three different classes of antihyperglycemic drugs have shown promise in treating NAFLD: SGLT2 inhibitors, peroxisome proliferator-activated receptor (PPAR) agonists, and glucagon-like peptide 1 (GLP-1) receptor agonists. Specifically, the researchers found that SGLT2 inhibitors (mostly dapagliflozin and empagliflozin) reduced liver fat content.

Learn more about SGLT2 inhibitors.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.